NCT06512337Active, not recruiting
A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China
A Prospective Observational Study to Evaluate the Effectiveness of Deucravacitinib in Patients With Moderate Plaque Psoriasis in Real-World Settings in China (ADMIRE)
Source: ClinicalTrials.gov · Last updated 15 Apr 2026
Brief summary (registry, in English)
The purpose of this study is to collect and evaluate real-world data on the effectiveness of deucravacitinib treatment in adults with moderate plaque psoriasis in China.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 153 (actual)
- First submitted
- 16 Jul 2024
- Start date
- 20 Jan 2025
- Primary completion date
- 11 Mar 2027
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Psoriasis
- NCT number
- NCT06512337
What you commit to
- Study type: Observational
- Participants enrolled: 153
- From 20 Jan 2025 to the primary completion date, 11 Mar 2027
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant use of other systemic treatments for psoriasis at baseline
- Prior treatment of deucravacitinib
Other
- Participating in or planning to participate in an interventional clinical trial
Who the study is looking for
- Participant aged 18 years or older
- Physician-reported (dermatologist) diagnosis of moderate plaque psoriasis with Body Surface Area ≥ 3% and \< 10%
- Participant newly initiated deucravacitinib according to the label
- Provided written informed consent to participate in the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Local Institution - 0003 Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| Local Institution - 0005 Coordinator of this site? Confirm its status | Dalian | China | Unknown status |
| Local Institution - 0001 Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
| Local Institution - 0002 Coordinator of this site? Confirm its status | Handan | China | Unknown status |
| Local Institution - 0004 Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
Related publications
- Real-world outcomes of deucravacitinib in Chinese plaque psoriasis patients: a 24-week prospective study.J Dermatolog Treat · 2026 · PMID 41769731
This page is information, not medical advice. Discuss any trial with your doctor.